Diabetic peripheral neuropathy (DPN) is among the most common and consequential complications of both type 1 and type 2 diabetes, affecting up to half of all people living with the disease over their lifetime. It is a leading cause of lower-limb amputation and of disabling neuropathic pain, and the loss of protective sensation it produces is the central reason that a minor blister or callus can progress unnoticed to a deep, limb-threatening ulcer. A defining and dangerous feature of DPN is that it is frequently silent in its earliest stages: nerve fibres are injured and protective sensation begins to erode long before a patient notices numbness, tingling, or pain. Because established nerve damage cannot be reversed, early detection is one of the few genuine opportunities to change the trajectory of the disease.
Why Early Detection Matters
The clinical stakes of missed or late diagnosis are substantial. Once symptoms and measurable sensory deficits have developed, the underlying nerve injury is generally irreversible, so the window in which intervention can prevent or slow progression occurs early, often before the patient is aware of any problem. This is why screening is treated as a preventive tool rather than simply a diagnostic one. Reviews of DPN emphasise that timely identification of at-risk feet allows clinicians to intensify metabolic and cardiovascular risk-factor control and to begin structured foot-protection strategies before ulceration occurs (Selvarajah et al., Lancet Diabetes & Endocrinology, 2019; Carmichael et al., Frontiers in Endocrinology, 2021).
The contrast with diabetic eye disease is instructive. The introduction of national retinopathy screening programmes has reduced the prevalence of blindness in working-age adults, yet diabetes-related amputation rates have not fallen in the same way. Authors have argued that a comparable, systematic approach to detecting neuropathy and the at-risk foot represents the best prospect for reducing these devastating outcomes (Selvarajah et al., 2019).
How Neuropathy Is Detected in Practice
Practical screening for the loss of protective sensation relies on a small set of simple, inexpensive bedside tests rather than specialised equipment. The International Working Group on the Diabetic Foot (IWGDF) framework centres on examination with a 10 g Semmes-Weinstein monofilament, a 128 Hz tuning fork for vibration perception, and assessment of light touch and reflexes.
The Problem of Diagnostic Variability
One important caveat is that the recorded prevalence of DPN varies dramatically depending on which diagnostic criteria are applied. In a cross-sectional study of 111 patients, the proportion identified as having neuropathy ranged from roughly 13% to 69% across different published guideline definitions. The most commonly affected sensory parameters were loss of vibration perception and absent ankle reflexes, and the IWGDF approach combining monofilament, cotton wisp, and tuning fork showed the highest level of agreement with other criteria (Chicharro-Luna et al., Primary Care Diabetes, 2019). This variability underscores why consistent, structured use of a validated screening protocol matters: the test used directly influences whether an at-risk foot is recognised.
Emerging Point-of-Care Tools
Because conventional bedside tests detect neuropathy relatively late, considerable research has focused on point-of-care devices capable of identifying small-fibre nerve damage earlier in the disease. Corneal confocal microscopy, which quantifies small nerve fibres in the cornea, and sudomotor and nerve-conduction point-of-care systems have been investigated as tools to detect early neuropathic change and to stage progression more accurately. These technologies are promising for earlier diagnosis and as surrogate markers in research, though their role in routine practice is still being defined (Carmichael et al., 2021; Sloan, Selvarajah & Tesfaye, Nature Reviews Endocrinology, 2021).
What Detection Enables: Risk-Factor Management
Identifying neuropathy early is only valuable if it leads to action. The evidence on prevention differs by diabetes type. Tight glycaemic control clearly prevents the development of DPN in type 1 diabetes, but in type 2 diabetes the benefit of glucose control alone is modest or absent, likely because of accompanying metabolic factors. The metabolic syndrome—obesity, hypertension, and dyslipidaemia—has emerged as a major risk factor for DPN in type 2 diabetes, which has shifted emphasis toward multifactorial risk-factor management and lifestyle intervention rather than glucose alone (Elafros et al., Lancet Neurology, 2022).
Beyond the classic distal symmetric polyneuropathy that threatens the foot, diabetic neuropathy encompasses a spectrum that includes autonomic forms affecting the cardiovascular, gastrointestinal, and urogenital systems. In the continued absence of disease-modifying therapies, prevention and early diagnosis remain the priority across this spectrum (Dillon, Ang & Pop-Busui, Annual Review of Medicine, 2024).
Key Takeaways
Diabetic peripheral neuropathy is common, frequently silent in its early stages, and largely irreversible once established, which makes early detection clinically critical. Simple, validated bedside tests—particularly the 10 g monofilament combined with vibration and reflex assessment—remain the foundation of screening for the loss of protective sensation, while emerging point-of-care technologies may push detection earlier. Diagnostic results vary by the criteria used, so consistent application of a structured protocol is essential. Ultimately, detection matters because it opens the door to multifactorial risk-factor control and foot-protection strategies that offer the best available means of preventing ulceration and amputation.
References
Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. The Lancet Diabetes & Endocrinology. 2019;7(12):938–948.
Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. Frontiers in Endocrinology. 2021;12:671257.
Chicharro-Luna E, Pomares-Gómez FJ, Ortega-Ávila AB, Coheña-Jiménez M, Gijon-Nogueron G. Variability in the clinical diagnosis of diabetic peripheral neuropathy. Primary Care Diabetes. 2019;14(1):53–60.
Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nature Reviews Endocrinology. 2021;17(7):400–420.
Elafros MA, Andersen H, Bennett DL, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. The Lancet Neurology. 2022;21(10):922–936.
Dillon BR, Ang L, Pop-Busui R. Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment. Annual Review of Medicine. 2024;75:293–306.
Comments
